Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study

Stock Information for Protagenic Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Protagenic Therapeutics Inc.

Results from Phase 1 Multiple-Dose Study of PT00114
Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq - INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq - PTIX)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VIGL, TXNM, SVT, PTIX on Behalf of Shareholders
Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.